Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML

(2009) S. Schnittger et al.   BLOOD

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

(2009) Daniela Cilloni et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

(2009) David Grimwade et al.   JOURNAL OF CLINICAL ONCOLOGY

Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals

(2008) Hans Beier Ommen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Monitoring minimal residual disease in acute myeloid leukaemia withNPM1mutations by quantitative PCR: clonal evolution is a limiting factor

(2008) Christina Papadaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation

(2008) Ulrike Bacher et al.   EXPERIMENTAL HEMATOLOGY

Development of Minimal Residual Disease–Directed Therapy in Acute Myeloid Leukemia

(2008) Sylvie D. Freeman et al.   SEMINARS IN ONCOLOGY